

Assessing response to treatment of exacerbations of bronchiectasis in adults

M.P. Murray, K. Turnbull, S. MacQuarrie and A.T. Hill

ABSTRACT: The present study aimed to assess the effect of intravenous antibiotic therapy on clinical and laboratory end-points in exacerbations of noncystic fibrosis bronchiectasis and to determine whether the outcomes were influenced by the pathogenic organism isolated.

A prospective cohort study was conducted from November 2006 to March 2008 of exacerbations requiring intravenous antibiotics. End-points included 24-h sputum volume, forced expiratory volume in one second (FEV1), forced vital capacity (FVC), incremental shuttle walk test, qualitative sputum microbiology, white cell count, erythrocyte sedimentation rate, C-reactive protein (CRP) and St George's Respiratory Questionnaire (SGRQ). Exacerbations due to *Pseudomonas aeruginosa* were compared with exacerbations due to other potential pathogenic organisms.

In total, 32 exacerbations were studied. Following 14 days of intravenous antibiotics, all outcomes significantly improved independent of a pathogenic organism, except FEV1 and FVC. The most responsive markers were: 24-h sputum volume (reduced in all patients and 80% had \geqslant 50% reduction); sputum bacterial clearance (78.1%); CRP (\geqslant 75% reduction in 62.5%) and SGRQ (\geqslant 4 unit improvement in 89.7%). CRP, 24-h sputum volume and SGRQ improved independent of microbial clearance.

In the current study, 24-h sputum volume, microbial clearance, C-reactive protein and St George's Respiratory Questionnaire were the most useful parameters to assess response to treatment of exacerbations of bronchiectasis. Outcomes were similar independent of the pathogenic organism with the exception of forced expiratory volume in one second and forced vital capacity.

KEYWORDS: Exacerbations, noncystic fibrosis bronchiectasis, treatment

nfective exacerbations are a significant cause of morbidity in noncystic fibrosis bronchiectasis and often necessitate utilisation of healthcare resources including in-patient admissions for intravenous antibiotic therapy [1]. The criteria used to define exacerbations requiring antibiotic therapy have been described in chronic obstructive pulmonary disease and include increasing dyspnoea, increasing sputum production and worsening sputum purulence [2]. Similarly, in bronchiectasis, antibiotics are prescribed during exacerbations in patients with increasing cough, increasing sputum volume and worsening sputum purulence. Little is known about how best to assess the effect of antibiotic treatment in the management of such exacerbations. Currently, a successful outcome is only qualitative, relying on the patient's subjective assessment of symptom resolution. Validated, easily accessible and relevant outcome measures are needed [3].

It is not known if the outcome of an exacerbation is influenced by the pathogenic organism. It has been shown that patients who are chronically colonised with *Pseudomonas aeruginosa* have more severe bronchiectasis, a poorer health-related quality of life (HRQoL) and may have an accelerated decline in forced expiratory volume in one second (FEV1) [4–7].

The aim of the present prospective cohort study was to assess the effect of 2 weeks of *i.v.* antibiotic therapy for exacerbations of noncystic fibrosis bronchiectasis on a variety of both clinical and laboratory end-points including 24-h sputum volume, FEV1, forced vital capacity (FVC), exercise capacity, systemic inflammation, sputum microbiology and HRQoL. In addition, the study aimed to determine whether these outcomes were influenced by the pathogenic organism isolated.

METHODS

The current study was a prospective cohort conducted from November 2006 to March 2008 of adults with infective exacerbations of noncystic fibrosis bronchiectasis requiring *i.v.* antibiotics. Ethical approval was obtained from the Lothian Research Ethics Committee (Edinburgh, UK).

AFFILIATIONS

Dept of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.

CORRESPONDENCE
M.P. Murray
Dept of Respiratory Medicine
51 Little France Crescent
Old Dalkeith Road
Edinburgh
EH16 4SA
LIK

Fax: 44 1312421870 E-mail: maevemurray@hotmail.com

Received: August 08 2008 Accepted after revision: September 23 2008

SUPPORT STATEMENT M.P. Murray is funded by the Chief Scientist Office, Edinburgh, UK.

STATEMENT OF INTEREST None declared.

European Respiratory Journal Print ISSN 0903-1936 Online ISSN 1399-3003 An exacerbation was defined as having clinical deterioration with all of the following symptoms: increasing cough; increasing sputum volume; and worsening sputum purulence. Criteria for *i.v.* antibiotic therapy included failure of oral antibiotics, culture of pathogenic organisms sensitive only to *i.v.* agents or severe exacerbations necessitating acute inpatient admission.

Exclusion criteria were: cystic fibrosis; active tuberculosis; active allergic bronchopulmonary aspergillosis; active sarcoid; patients on long-term antibiotic therapy (oral or nebulised); and patients with mixed normal flora isolated from their sputum at the start of the exacerbation.

All patients received 14 days of *i.v.* antibiotic therapy; the antibiotics chosen were based on sputum microbiology prior to commencing treatment or, if necessary, previous sputum microbiology history. All patients were advised to continue chest physiotherapy. Any patient on long-term oral corticosteroid therapy had their dose doubled for the first 7 days of the exacerbation. No other adjunctive treatments were used to manage the exacerbation.

The following clinical and laboratory outcome measures were assessed immediately prior to commencing antibiotic therapy (day 0) and on the completion of antibiotics (day 14).

Clinical assessments

Patients collected their sputum over a 24-h period in clear sterile pots (maximum volume of 45 mL·pot⁻¹) and the total volume was measured. No microbiological analysis was performed on this sample.

FEV1 and FVC were recorded to measure lung function. The FEV1/FVC ratio was calculated. A clinically significant response was >12% and >200 mL improvement from the start of exacerbation [8].

An externally paced, 10-m incremental field walking test was used to measure exercise capacity [9].

Laboratory assessments

Qualitative sputum bacteriology was performed on a fresh, early morning sputum sample.

Systemic inflammation was measured by white cell count (WCC), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

HRQoL assessment

The St George's Respiratory Questionnaire (SGRQ) was completed at the start of the exacerbation and 1 week following antibiotic completion [10]. The questionnaire was adapted for the end of exacerbation assessment to ask about symptoms in the preceding week (*i.e.* the week following antibiotic completion).

The SGRQ is a 50 item self-administered HRQoL questionnaire consisting of three components: symptoms (eight items); activity (16 items); and impacts (26 items). It has previously been validated to reflect impaired HRQoL in bronchiectasis patients [10]. The total score ranges from 0–100; a higher score indicates a poorer HRQoL. A 4-unit difference in the total

SGRQ score has been established as a clinically significant change [10].

Statistics

The data was normally distributed and are presented as mean \pm SD. For comparing means, a paired t-test was used. Patients that isolated *P. aeruginosa* were compared with those that isolated other potential pathogenic microorganisms (PPMs) at the start of the exacerbation. Fisher's exact test was used to compare groups. A two tailed p-value of <0.05 was considered to be statistically significant. Additional subanalysis was conducted to ensure that the reason for needing *i.v.* therapy or patients who went on to experience multiple exacerbations did not influence the results.

RESULTS

Patients

There were 58 exacerbations of noncystic fibrosis bronchiectasis managed with 2 weeks of *i.v.* antibiotic therapy during the study period. In total, 13 patients had more than one exacerbation during the study period, but only the first exacerbation for each patient was used. Five patients were excluded as mixed normal flora was isolated at the start of the exacerbation and one patient was excluded because they had mucoid sputum at presentation. The final analysis was conducted in 32 individual patients.

Table 1 details baseline patient characteristics, including parameters of disease severity and table 2 provides details of the aetiology of the bronchiectasis. All patients had advanced bronchiectasis with 29 (90.6%) patients being chronically colonised with pathogenic bacteria in the sputum when clinically stable (65.6% had *P. aeruginosa*) and having experienced multiple exacerbations in the past year (table 1). Overall,

TABLE 1 Patient characteristics	
Subjects n	32
Male	10 (31.3)
Age yrs	62.8±9.8
Nonsmokers	23 (71.9)
Ex-smokers	9 (28.1)
Ex-smoker pack-yr history	34.5 ± 17.2
COPD	3 (9.4)
Asthma	18 (56.3)
Inhaled corticosteroid therapy	28 (87.5)
Nebulised bronchodilator therapy	7 (21.9)
FEV ₁ L	1.57 ± 0.58
FEV ₁ % predicted	66.5 ± 27.3
FVC L	2.49 ± 0.78
FVC % predicted	85.3 ± 33.2
Infective exacerbations in preceding year	7.4 ± 6.0
Number of lobes involved on HRCT	4.1 ± 1.7
Cystic bronchiectasis	10 (31.2)
Chronically colonised	29 (90.6)

Data are expressed as n (%) or mean ± sp, unless otherwise stated. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HRCT: high-resolution computed tomography.



EUROPEAN RESPIRATORY JOURNAL VOLUME 33 NUMBER 2 313

62.5% needed *i.v.* antibiotics because of failure of oral antibiotics, 34.4% had severe exacerbations necessitating acute in-patient admission and 3.1% required *i.v.* antibiotics as the pathogenic organisms isolated were sensitive only to agents available as *i.v.* preparations.

Sputum bacteriology

At the start of the exacerbation *P. aeruginosa* was isolated in 19 patients; 10 had nonmucoid and nine had mucoid *P. aeruginosa*. In total, 13 patients isolated other PPMs which included *Haemophilus influenzae* (n=4), *Streptococcus pneumoniae* (n=3), *Staphylococcus aureus* (n=2), *Moraxella catarrhalis* (n=2), *Escherichia coli* (n=1) and *Serratia* species (n=1).

Antibiotic therapy

All patients completed 14 days of antibiotic therapy and doses used were as recommended for bronchiectasis/cystic fibrosis in the British National Formula [11]. In the *P. aeruginosa* group, 13 patients received *i.v.* ceftazidime (2 g three times daily) and gentamicin (dose per ideal body weight and creatinine clearance); two patients with a previous history of gentamicin toxicity received *i.v.* ceftazidime (2 g three times daily) and colistin (2 MU three times daily) and three patients with known impaired renal function received *i.v.* ceftazidime (2 g twice daily) and oral ciprofloxacin (500 mg twice daily). The remaining patient who had a known intolerance of ceftazidime received *i.v.* piperacillin with tazobactam (4.5 g three times daily) and oral ciprofloxacin (500 mg twice daily).

In the patients with other PPMs isolated, those with isolated *H. influenzae*, *S. pneumoniae* and *M. catarrhalis* all received the single agent ceftriaxone (2 g once daily). The two patients with isolated *S. aureus* (one methicillin-sensitive *S. aureus* and one methicillin-resistant *S. aureus*) received *i.v.* flucoxacillin (500 mg four times daily) and vancomycin (dose per ideal body weight and creatinine clearance), respectively. The remaining two patients had isolated *Serratia* spp. and *E. coli* and both were managed with *i.v.* ceftazidime (2 g three times daily) and gentamicin (dose per ideal body weight and creatinine clearance).

Corticosteroids

In total, four patients were receiving long-term oral corticosteroid therapy and had their dose doubled for 7 days. Otherwise no patients received oral corticosteroid therapy.

TABLE 2 Aetiology of bronchiectasis				
Inactive allergic bronchopulmonary aspergillosis Burnt out sarcoidosis Post infective (pneumonia, tuberculosis, pertussis,	11 (34.4) 1 (3.1) 10 (31.3)			
measles) Ig deficiency (all IgG subclass 2) Ciliary dyskinesia Idiopathic	4 (12.5) 1 (3.1) 5 (15.6)			
Data are presented as n (%). lg: immunoglobulin.				

Side-effects

No adverse side-effects were reported and no changes to treatment regimes occurred. All patients successfully completed 14 days of treatment.

Outcomes: clinical assessments

24-h sputum volume

Following 14 days of antibiotics the 24-h sputum volume of all patients reduced with a mean reduction of 21.8 ± 19.9 mL (p<0.0001; table 3).

All patients had a reduction in their 24-h sputum volume: 5% had <25% improvement, 15% had 25–49% reduction and 80% had >50% reduction (fig. 1).

Pulmonary function tests

The FEV1 did not significantly improve, with a mean \pm SD increase of 0.07 ± 0.2 L $(5.4\pm12.5\%; p=0.07; table 3)$. The FVC did, however, improve by a mean of 0.09 ± 0.44 L $(2.9\pm22.2\%; p=0.01; table 3)$.

Overall, 29% of patients did not have any improvement in FEV1, 51.6% had an improvement of \leq 12% or \leq 200 mL, 19.4% had an improvement of \geq 12% and \geq 200 mL (fig. 1).

Exercise capacity

The distance achieved in the incremental field walking test significantly improved by $58.3 \pm 51.0 \text{ m}$ ($48.9 \pm 54.8\%$; p<0.0001; table 3), following 2 weeks of antibiotic treatment.

In total, 12% of patients did not show an improvement in exercise capacity, 28% had <25% improvement, 28% had 25–49% improvement and 36% of patients had an improvement of $\geq 50\%$ (fig. 1).

Outcomes: laboratory assessments

Systemic inflammation

There was a significant improvement in WCC, ESR and CRP (table 3). WCC reduced by a mean of $3.7\pm3.7\times10^9\cdot L^{-1}$, ESR reduced by a mean of $17.7\pm20.9~\text{mm}\cdot\text{h}^{-1}$ and CRP reduced by a mean of $59.5\pm69.6~\text{mg}\cdot\text{L}^{-1}$ (table 3).

WCC did not improve in 9.7% of patients, 29% had 50–74% improvement and no patients had a \geqslant 75% improvement in WCC (fig. 1). ESR did not improve in 30% of patients, 40% had a 50–74% improvement and 7% had a \geqslant 75% improvement in ESR (fig. 1). CRP did not improve in 9.3% of patients, 15.6% had a 50–74% improvement and 62.5% had a \geqslant 75% improvement in CRP (fig. 1).

Sputum microbiology

Qualitative bacterial clearance was achieved in 78.1% of patients (p<0.0001; fig. 1). All patients infected with other PPMs achieved bacterial clearance. Overall, 12 out of 19 patients infected with P. aeruginosa achieved bacterial clearance. Of the seven patients with P. aeruginosa who did not achieve bacterial clearance, five of these had a mucoid strain. Although microbial clearance was greater in patients with other PPMs compared with patients infected with P. aeruginosa, this difference did not achieve statistical significance (p=0.07).

TABLE 3 Outcome measures from start to end of e	exacerbation		
Variable	Start of exacerbation	End of exacerbation	p-value
24-h sputum volume mL	30.4±21.9	8.5 ± 8.4	<0.0001
FEV1 L FVC L	1.45 ± 0.57 $2.35 + 0.78$	1.52 ± 0.58 2.5 + 0.86	0.07 0.01
FEV1/FVC	61.4 ± 12.3	60.4 ± 11.5	0.5
Exercise capacity m WCC* x109·L ⁻¹	217.0±168.0 10.8+7.1	271 ± 184.0 7.2 + 2.5	<0.0001 <0.0001
ESR mm·h ⁻¹	40.1 ± 27.4	22.3 ± 14.1	<0.0001
CRP mg·L ⁻¹	66.9±70.7	7.4 ± 11.2	< 0.0001

Data are presented as mean \pm sp, unless otherwise stated. FEV1: forced expiratory volume in one second; FVC: forced vital capacity; WCC: white cell count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein. *: normal range 4–11 × 10 9 ·L⁻¹.

HRQoL

There was a significant improvement in all of the individual domain scores of the SGRQ following completion of antibiotics (table 4). The total score significantly improved with a mean reduction of 13.8 ± 12.9 units (p=0.01; table 4). In total, 7.1% did not show any improvement in SGRQ score, 3.6% had an improvement of <4 units and 89.3% had an improvement of >4 units.

Pathogenic organisms

The response to treatment was compared between patients with P. aeruginosa and other PPMs. The responses were not significantly different with the exception of FEV1 and FVC. Patients infected with P. aeruginosa showed no improvement in either FEV1 (value at start of exacerbation was 1.52 ± 0.61 L improving to only 1.53 ± 0.58 L at the end; p=0.9) or in FVC (value at start of exacerbation 2.38 ± 0.88 L improving to 2.44 ± 0.81 L; p=0.3). Those patients infected with other PPMs did, however, have a significant improvement in both

FEV1 (improving from 1.32 ± 0.48 L to 1.51 ± 0.61 L; p=0.01) and FVC (improving from 2.25 ± 0.62 L to 2.58 ± 0.96 L; p=0.02).

Failure of microbial clearance

Despite failure of microbial clearance, there were significant improvements in the three most responsive end-points: 24-h sputum volume (mean \pm SD reduction 13.8 \pm 9.1 mL; p= 0.007), CRP (mean \pm SD reduction 61.4 \pm 104.4 mg·L⁻¹; p=0.03) and SGRQ score (mean \pm SD reduction 14.8 \pm 7.2 units; p=0.004).

Need for i.v. antibiotics

In total, 11 patients required *i.v.* antibiotics because of failure of oral antibiotics, one patient due to culture of pathogenic organisms sensitive only to *i.v.* agents and 20 patients due to severe exacerbations necessitating acute in-patient admission.

At the start of the exacerbation, the need for hospitalisation group had worse exercise capacity (-196 \pm 59.3 m; p=0.003), higher CRP (49.8 \pm 23.4 mg·L⁻¹; p=0.04) and WCC (2.8 \pm 1.3 ×




FIGURE 1. Changes in clinical markers following 2 weeks of intravenous antibiotic therapy. FEV1: forced expiratory volume in one second, WCC: white cell count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SGRQ: St George's Respiratory Questionnaire.

TABLE 4	Individual domain and total St George's Respiratory Questionnaire scores from start to end of exacerbation				
Domain	Start of exacerbation	End of exacerbation	p-value		
Symptoms	76.4 ± 12.9	51.7 ± 23.1	< 0.0001		
Activity	65.5 ± 26.4	57.4 ± 26.5	0.01		
Impact	47.9 ± 18.4	37.2 ± 19.2	< 0.001		
Total score	57.9 ± 17.5	45.7 ± 20.0	< 0.0001		
Data are presented as mean ± sp, unless otherwise stated.					

 $10^9 \cdot L^{-1}$; p=0.04) and worse SGRQ score (14.4 ± 5.8 units; p=0.02). There was no significant difference in the other endpoints. Both groups showed a significant improvement in all parameters except in FEV1 and FVC.

Single versus multiple exacerbations

In total, 19 patients had one exacerbation necessitating i.v. antibiotics and 13 required more than one course of i.v. antibiotics (3.6 \pm 1.5 courses). At the start of the exacerbation there was no difference in the end-points between groups. Patients with a single exacerbation had a significant improvement in all parameters except in FEV1 and FVC. Patients with more than one exacerbation had a significant improvement in all parameters except FEV1.

DISCUSSION

The present prospective cohort study identified useful clinical and laboratory markers for assessing the response to 2 weeks' *i.v.* antibiotic treatment in adults with exacerbations of noncystic fibrosis bronchiectasis. Improvements were observed in 24-h sputum volume, sputum bacterial clearance, systemic inflammation, exercise capacity and HRQoL and independent of pathogenic organism. No improvement was observed in FEV1. Microbial clearance, 24-h sputum volume, CRP and SGRQ were the most responsive markers identified.

All patients received 14 days of *i.v.* antibiotic therapy. The optimum duration of treatment is not known and further trials are needed to define this period but previous studies have administered therapy for between 5 to 28 days [12–15].

All patients with *P. aeruginosa* or Gram-negative organisms were treated with two anti-pseudomonal antibiotics to reduce the chance of developing antibiotic resistance. Those with other PPMs were treated with monotherapy using *i.v.* ceftriaxone. The optimum therapeutic agents are unknown. The agents used in the current study are known from *in vitro* sensitivities to be effective agents. The aim of the present study was not to assess the therapeutic regimen but to explore the outcome of 2 weeks of effective antibiotic therapy on a variety of clinical and laboratory parameters.

There are no published international guidelines and no validated methods to allow clinicians to assess response to treatment. Currently, a successful outcome predominantly relies on the subjective assessment of symptom resolution. Thus, objective outcome measures are needed [3]. The present study sought to observe relevant, minimally invasive and

easily accessible end-points to assess parameters that may be clinically useful in monitoring response to therapy. Four particularly responsive markers were identified: 24-h sputum volume, qualitative sputum bacteriology, CRP and SGRQ score.

All patients had a significant improvement in 24-h sputum volume, with 80% having a \geqslant 50% reduction. Sputum volume in 24 h is a potentially useful marker as it is highly pertinent to the condition, noninvasive, easily accessible and inexpensive. It has been used as a marker in previous studies that have assessed potential long-term therapeutic strategies including inhaled steroids and long-term antibiotics [16–21]. A recent study has shown wet weight sputum to be as reliable as dry sputum [22]. The potential limitation of 24-h sputum volume as an outcome measure is the reliance on patient compliance for collection.

Sputum bacteriology as an end-point could involve either complete bacterial clearance or a reduction in bacterial load (colony-forming units·mL⁻¹). Direct counts of bacterial load is time consuming, expensive and less likely to be available in the majority of routine (nonresearch) microbiology laboratories. In the current study, 78.1% had bacterial clearance. In the remaining 22.9% no information on whether there was a reduction in bacterial load was found as only qualitative cultures were carried out. However, these patients did show improvements in the three other key parameters identified in the present study: 24-h sputum volume, CRP and SGRQ score. Further studies using both qualitative and quantitative cultures would be helpful, although at present, the current findings emphasise the need for more than one end-point to assess response to treatment.

The present authors observed a nine-fold fall in CRP (fall $59.5\pm69.6~{\rm mg\cdot L^{-1}}$), with 62.5% having a $\geqslant 75\%$ improvement following antibiotic therapy. The other markers of systemic inflammation that were observed were WCC and ESR. Although a significant improvement was seen in WCC (1.5-fold fall with a fall of $3.7\pm3.7\times10^9\cdot L^{-1}$), the mean WCC at the start of the exacerbation was within normal range and the reduction following antibiotics was small, suggesting WCC is a less relevant marker of treatment response. The mean ESR also improved (1.8-fold fall with a fall of $17.7\pm20.9~{\rm mm\cdot h^{-1}}$); however, only 7% of patients achieved $\geqslant 75\%$ reduction in ESR. Of these three markers, CRP was most responsive to change.

In total, 89.7% of patients showed a clinically significant response (*i.e.* \geq 4 unit improvement) in SGRQ score. The use of such questionnaires remains predominantly within the research setting as administration and analysis require specific resources and are time consuming.

In keeping with the observed clinical improvements, exercise capacity improved by 1.2-fold with a rise of 54.1 ± 51.5 m and 36% of patients increasing their distance in the incremental field walking test by $\geqslant 50\%$. It may be a useful adjunct to other markers.

There was no significant improvement in FEV1 but there was a small 1.06-fold rise in FVC (rise of 144 ± 306 mL). However, there was an improvement seen in FEV1 in patients infected

316 VOLUME 33 NUMBER 2 EUROPEAN RESPIRATORY JOURNAL

with other PPMs, which may reflect the complete bacterial clearance achieved in the current group. A recent review article of exacerbations in bronchiectasis noted FEV1 to be a less sensitive measure in acute exacerbations, particularly in contrast to cystic fibrosis bronchiectasis [3]. Similar findings were made by the authors of a previous study who found that following 2 weeks of treatment with oral amoxicillin there were small improvements in FEV1 (mean improvement 8 mL) and FVC (mean improvement 180 mL), but these changes were not felt to be clinically useful [23].

In the present study, 24-h sputum volume, microbial clearance, C-reactive protein and St George's Respiratory Questionnaire were the most useful parameters to assess response to treatment of exacerbations of bronchiectasis. Outcomes were similar and independent of the pathogenic organism with the exception of forced expiratory volume in one second and forced vital capacity.

ACKNOWLEDGEMENTS

The current authors gratefully acknowledge the assistance from J. Pentland and W. Pollock with the incremental shuttle walk test and J. Scott with pharmacy input (all Dept of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK). The present authors would also like to thank P. Jones (St George's University of London, London, UK) for his kind permission to use the St George's Respiratory Ouestionnaire.

REFERENCES

- 1 Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. *Eur J Intern Med* 2003; 14: 488–492.
- **2** Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987; 106: 196–204.
- **3** Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4 Noncystic fibrosis bronchiectasis. *Thorax* 2008; 63: 269–276.
- **4** Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. *Chest* 2007; 132: 1565–1572.
- **5** Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of *Pseudomonas aeruginosa*. Eur Respir J 1996; 9: 1601–1604.
- **6** Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. *Eur Respir J* 1997; 10: 1754–1760.
- **7** Ho PL, Chan KN, Ip MS, *et al*. The effect of *Pseudomonas aeruginosa* infection on clinical parameters in steady-state bronchiectasis. *Chest* 1998; 114: 1594–1598.

- **8** Pellegrino R, Viegi G, Brusasco V, *et al.* Interpretative strategies for lung function tests. *Rev Mal Respir* 2007; 24: 83–108.
- **9** Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. *Thorax* 1999; 54: 213–222.
- **10** Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. *Am J Respir Crit Care Med* 1997; 156: 536–541.
- **11** British Medical Association and Royal Pharmaceutical Society of Great British National Formulary. 55th Edn. London, Pharmaceutical Press, 2008.
- **12** Darley ES, Bowker KE, Lovering AM, Harvey JE, Macgowan AP. Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis. *J Antimicrob Chemother* 2000; 45: 247–250.
- **13** Chan TH, Ho SS, Lai CK, *et al.* Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. *Chemotherapy* 1996; 42: 150–156.
- **14** Ip M, Shum D, Lauder I, Lam WK, So SY. Effect of anti-biotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. *Respir Med* 1993; 87: 449–454.
- **15** Tsang KW, Chan WM, Ho PL, Chan K, Lam WK, Ip MS. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. *Eur Respir J* 1999; 14: 1206–1209.
- **16** Tsang KW, Tan KC, Ho PL, *et al.* Inhaled fluticasone in bronchiectasis: a 12 month study. *Thorax* 2005; 60: 239–243.
- **17** Tsang KW, Ho PI, Chan KN, *et al.* A pilot study of low-dose erythromycin in bronchiectasis. *Eur Respir J* 1999; 13: 361–364.
- **18** el-Din MA, Palmer LB, el-Tayeb MN, Khalil I, Gabr MS. Nebulizer therapy with antibiotics in chronic suppurative lung disease. *J Aerosol Med* 1994; 7: 345–350.
- **19** Cymbala AA, Edmonds LC, Bauer MA, *et al.* The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. *Treat Respir Med* 2005; 4: 117–122.
- **20** Currie DC, Garbett ND, Chan KL, *et al.* Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. *Q J Med* 1990; 76: 799–816.
- **21** The Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. *Br Med J* 1957; 2: 255–259.
- **22** Moran F EJS, Moffitt K, Piper A, Bradley JM. Is sputum load a useful outcome measure for clinical trials in bronchiectasis? *Thorax* 2006; 61: Suppl. 2, 1–133.
- **23** Hill SL, Stockley RA. Effect of short and long term antibiotic response on lung function in bronchiectasis. *Thorax* 1986; 41: 798–800.